OR WAIT 15 SECS
The fill line will work to manufacture high-value APIs for drug product manufacturing to meet the needs of the COVID-19 pandemic.
LSNE Contract Manufacturing, a US-based contract development and manufacturing organization, announced on Jan. 14, 2021 that it has expanded its vial filling and lyophilization capacity with the addition of a new automated aseptic fill line at its facility in Bedford, NH.
The fill line will work to manufacture high-value APIs for drug product manufacturing to meet the needs of the COVID-19 pandemic, LSNE said in a company press release. The new addition will focus on products that require minimum process loss because of API availability or high cost and will feature in-line (non-destructive) weight checks and disposable formulation and manufacturing materials.
“LSNE continues to innovate and expand our global capacity and capabilities to better serve pharmaceutical companies with their ever changing clinical and commercial programs. By investing in this new GMP sterile fill finish capacity on our Bedford, NH campus, we continue to execute on our corporate growth strategy and better serve our client’s needs, especially where product loss is a key consideration,” said Shawn Cain, chief operating officer, LSNE, in the press release.
The new fill suite is set to be qualified and ready for manufacturing in the third quarter of 2021.